Taysha Gene Therapies Stock Performance
| TSHA Stock | USD 4.65 0.07 1.53% |
On a scale of 0 to 100, Taysha Gene holds a performance score of 5. The entity has a beta of 1.73, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Taysha Gene will likely underperform. Please check Taysha Gene's downside variance, daily balance of power, period momentum indicator, as well as the relationship between the skewness and day typical price , to make a quick decision on whether Taysha Gene's existing price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Taysha Gene Therapies are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating technical indicators, Taysha Gene sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.66 | Five Day Return (3.17) | Year To Date Return (12.76) | Ten Year Return (80.96) | All Time Return (80.96) |
1 | Disposition of 260047 shares by Nagendran Sukumar of Taysha Gene at 1.71 subject to Rule 16b-3 | 12/01/2025 |
2 | Disposition of 111324 shares by Nagendran Sukumar of Taysha Gene at 0.6989 subject to Rule 16b-3 | 01/12/2026 |
3 | Taysha Gene Therapies Inc. A Promising Biotech on Rett Syndrome Drug Prospects | 01/14/2026 |
4 | Disposition of 78968 shares by Alam Kamran of Taysha Gene at 4.75 subject to Rule 16b-3 | 01/23/2026 |
5 | Disposition of 23849 shares by Alam Kamran of Taysha Gene at 4.61 subject to Rule 16b-3 | 01/26/2026 |
6 | Disposition of 136789 shares by Sean Nolan of Taysha Gene at 4.75 subject to Rule 16b-3 | 01/27/2026 |
7 | Heres What Analysts Are Saying About Taysha Gene Therapies | 01/29/2026 |
8 | Taysha Gene Therapies, Inc. Receives Consensus Rating of Moderate Buy from Analysts - MarketBeat | 01/30/2026 |
9 | Acquisition by Sean Nolan of 444444 shares of Taysha Gene at 0.9 subject to Rule 16b-3 | 02/02/2026 |
10 | Disposition of 1655 shares by Alam Kamran of Taysha Gene at 4.52 subject to Rule 16b-3 | 02/04/2026 |
11 | Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 | 02/06/2026 |
| Begin Period Cash Flow | 146.5 M | |
| Total Cashflows From Investing Activities | -363 K |
Taysha Gene Relative Risk vs. Return Landscape
If you would invest 399.00 in Taysha Gene Therapies on November 20, 2025 and sell it today you would earn a total of 59.00 from holding Taysha Gene Therapies or generate 14.79% return on investment over 90 days. Taysha Gene Therapies is currently generating 0.3341% in daily expected returns and assumes 4.535% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Taysha, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Taysha Gene Target Price Odds to finish over Current Price
The tendency of Taysha Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 4.65 | 90 days | 4.65 | about 67.16 |
Based on a normal probability distribution, the odds of Taysha Gene to move above the current price in 90 days from now is about 67.16 (This Taysha Gene Therapies probability density function shows the probability of Taysha Stock to fall within a particular range of prices over 90 days) .
Taysha Gene Price Density |
| Price |
Predictive Modules for Taysha Gene
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Taysha Gene Therapies. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Taysha Gene Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Taysha Gene is not an exception. The market had few large corrections towards the Taysha Gene's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Taysha Gene Therapies, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Taysha Gene within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.11 | |
β | Beta against Dow Jones | 1.73 | |
σ | Overall volatility | 0.54 | |
Ir | Information ratio | 0.03 |
Taysha Gene Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Taysha Gene for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Taysha Gene Therapies can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Taysha Gene had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 8.33 M. Net Loss for the year was (89.3 M) with profit before overhead, payroll, taxes, and interest of 6.31 M. | |
| Taysha Gene Therapies currently holds about 66.24 M in cash with (81.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.61. | |
| Taysha Gene has a frail financial position based on the latest SEC disclosures | |
| Over 89.0% of the company shares are owned by institutional investors | |
| Latest headline from thestar.com: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 |
Taysha Gene Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Taysha Stock often depends not only on the future outlook of the current and potential Taysha Gene's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Taysha Gene's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 250.1 M | |
| Cash And Short Term Investments | 139 M |
Taysha Gene Fundamentals Growth
Taysha Stock prices reflect investors' perceptions of the future prospects and financial health of Taysha Gene, and Taysha Gene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Taysha Stock performance.
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (16.19) % | ||||
| Current Valuation | 1.02 B | ||||
| Shares Outstanding | 273.92 M | ||||
| Price To Book | 5.69 X | ||||
| Price To Sales | 197.52 X | ||||
| Revenue | 8.33 M | ||||
| Gross Profit | 6.31 M | ||||
| EBITDA | (87.95 M) | ||||
| Net Income | (89.3 M) | ||||
| Cash And Equivalents | 66.24 M | ||||
| Cash Per Share | 1.61 X | ||||
| Total Debt | 63.18 M | ||||
| Debt To Equity | 1.93 % | ||||
| Current Ratio | 1.79 X | ||||
| Book Value Per Share | 0.80 X | ||||
| Cash Flow From Operations | (81.22 M) | ||||
| Earnings Per Share | (0.33) X | ||||
| Market Capitalization | 1.25 B | ||||
| Total Asset | 160.36 M | ||||
| Retained Earnings | (602.3 M) | ||||
| Working Capital | 115.9 M | ||||
About Taysha Gene Performance
By analyzing Taysha Gene's fundamental ratios, stakeholders can gain valuable insights into Taysha Gene's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Taysha Gene has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Taysha Gene has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.50) | (0.53) | |
| Return On Capital Employed | (0.78) | (0.74) | |
| Return On Assets | (0.50) | (0.53) | |
| Return On Equity | (1.44) | (1.51) |
Things to note about Taysha Gene Therapies performance evaluation
Checking the ongoing alerts about Taysha Gene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Taysha Gene Therapies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Taysha Gene had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 8.33 M. Net Loss for the year was (89.3 M) with profit before overhead, payroll, taxes, and interest of 6.31 M. | |
| Taysha Gene Therapies currently holds about 66.24 M in cash with (81.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.61. | |
| Taysha Gene has a frail financial position based on the latest SEC disclosures | |
| Over 89.0% of the company shares are owned by institutional investors | |
| Latest headline from thestar.com: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635 |
- Analyzing Taysha Gene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Taysha Gene's stock is overvalued or undervalued compared to its peers.
- Examining Taysha Gene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Taysha Gene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Taysha Gene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Taysha Gene's stock. These opinions can provide insight into Taysha Gene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Taysha Stock analysis
When running Taysha Gene's price analysis, check to measure Taysha Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Taysha Gene is operating at the current time. Most of Taysha Gene's value examination focuses on studying past and present price action to predict the probability of Taysha Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Taysha Gene's price. Additionally, you may evaluate how the addition of Taysha Gene to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |